BRAF and cancer: Although being still at their infancy, approaches based on the targeting of B-Raf with PROTACs technology are expected to provided novel valuable opportunities for cancer treatment and to help overcome drug resistances very often observed in marketed drugs, as recently discussed, for example, by Heet al. 111 Indeed, such approaches allow to also promote complete removal of the protein scaffold other than blocking its catalytic functions, which might represent a valuable advantage over already reported ATP-competitive inhibitors.